Cover Image
市場調查報告書

Emergent BioSolutions Inc.:產品平台分析

Emergent BioSolutions Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 240921
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
Emergent BioSolutions Inc.:產品平台分析 Emergent BioSolutions Inc. - Product Pipeline Review - 2016
出版日期: 2016年03月31日 內容資訊: 英文 68 Pages
簡介

本報告提供Emergent BioSolutions Inc.的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Emergent BioSolutions Inc.的基本資料

Emergent BioSolutions Inc.概要

  • 主要資訊
  • 企業資料

Emergent BioSolutions Inc.:R&D概要

  • 主要的治療範圍

Emergent BioSolutions Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Emergent BioSolutions Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 申請未受理/被撤消產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Emergent BioSolutions Inc.:藥物簡介

  • trenonacog alfa
  • NP-015
  • AV-7909
  • otlertuzumab
  • PreviThrax
  • AVP-21D9
  • Anti-CD19 X Anti-CD3
  • Anti-H5HA mAB
  • Anti-HER2 X Anti-CD3
  • Anti-RON X Anti-CD3
  • CTLA-4 X mono-IL-10
  • ES-210
  • ES-301
  • ES-306
  • ES-414
  • IB1-008
  • MVA-H5HA
  • MVA-RSV
  • 重組肉毒桿菌疫苗
  • TNFR x A2
  • TNFR x TWEAKR

Emergent BioSolutions Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Emergent BioSolutions Inc.:最近的開發平台趨勢

Emergent BioSolutions Inc.:暫停中的計劃

Emergent BioSolutions Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • Immune Globulin
    • Leucotropin
    • PEP-35
    • TST-10088

Emergent BioSolutions Inc.:企業發表

Emergent BioSolutions Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08014CDB

Summary

Global Markets Direct's, 'Emergent BioSolutions Inc. - Product Pipeline Review - 2016', provides an overview of the Emergent BioSolutions Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Emergent BioSolutions Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Emergent BioSolutions Inc.
  • The report provides overview of Emergent BioSolutions Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Emergent BioSolutions Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Emergent BioSolutions Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Emergent BioSolutions Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Emergent BioSolutions Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Emergent BioSolutions Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Emergent BioSolutions Inc. Snapshot
    • Emergent BioSolutions Inc. Overview
    • Key Information
    • Key Facts
  • Emergent BioSolutions Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Emergent BioSolutions Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Emergent BioSolutions Inc. - Pipeline Products Glance
    • Emergent BioSolutions Inc. - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
    • Emergent BioSolutions Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Emergent BioSolutions Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Emergent BioSolutions Inc. - Drug Profiles
    • coagulation factor IX (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-7909
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • otlertuzumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PreviThrax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ES-414
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 5-E3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • antihemophilic factor (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ES-210
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ES-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ES-306
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EV-035
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GC-072
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MVA-RSV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MVAH-5HA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Inhibit CD19 and CD3 for B-Cell Lymphoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MonoClonal Antibody for Ebola and Marburg Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Target HER-2 and CD3 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Target RON and CD3 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccines for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Emergent BioSolutions Inc. - Pipeline Analysis
    • Emergent BioSolutions Inc. - Pipeline Products by Target
    • Emergent BioSolutions Inc. - Pipeline Products by Route of Administration
    • Emergent BioSolutions Inc. - Pipeline Products by Molecule Type
    • Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action
  • Emergent BioSolutions Inc. - Recent Pipeline Updates
  • Emergent BioSolutions Inc. - Dormant Projects
  • Emergent BioSolutions Inc. - Dormant Projects
  • Emergent BioSolutions Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Anthrivig
      • Immune Globulin
      • Leucotropin
      • PEP-35
      • TST-10088
  • Emergent BioSolutions Inc. - Company Statement
  • Emergent BioSolutions Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Emergent BioSolutions Inc., Key Information
  • Emergent BioSolutions Inc., Key Facts
  • Emergent BioSolutions Inc. - Pipeline by Indication, 2016
  • Emergent BioSolutions Inc. - Pipeline by Stage of Development, 2016
  • Emergent BioSolutions Inc. - Monotherapy Products in Pipeline, 2016
  • Emergent BioSolutions Inc. - Partnered Products in Pipeline, 2016
  • Emergent BioSolutions Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Emergent BioSolutions Inc. - Filing rejected/Withdrawn, 2016
  • Emergent BioSolutions Inc. - Phase II, 2016
  • Emergent BioSolutions Inc. - Phase I, 2016
  • Emergent BioSolutions Inc. - Preclinical, 2016
  • Emergent BioSolutions Inc. - Discovery, 2016
  • Emergent BioSolutions Inc. - Pipeline by Target, 2016
  • Emergent BioSolutions Inc. - Pipeline by Route of Administration, 2016
  • Emergent BioSolutions Inc. - Pipeline by Molecule Type, 2016
  • Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action, 2016
  • Emergent BioSolutions Inc. - Recent Pipeline Updates, 2016
  • Emergent BioSolutions Inc. - Dormant Developmental Projects,2016
  • Emergent BioSolutions Inc. - Discontinued Pipeline Products, 2016
  • Emergent BioSolutions Inc., Other Locations
  • Emergent BioSolutions Inc., Subsidiaries

List of Figures

  • Emergent BioSolutions Inc. - Pipeline by Top 10 Indication, 2016
  • Emergent BioSolutions Inc. - Pipeline by Stage of Development, 2016
  • Emergent BioSolutions Inc. - Monotherapy Products in Pipeline, 2016
  • Emergent BioSolutions Inc. - Pipeline by Top 10 Target, 2016
  • Emergent BioSolutions Inc. - Pipeline by Route of Administration, 2016
  • Emergent BioSolutions Inc. - Pipeline by Molecule Type, 2016
  • Emergent BioSolutions Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top